Please Enable Cookies

www.cablinginstall.com is using a security service for protection against online attacks. This process is automatic. You will be redirected once the validation process is complete.

Recent Quotes
My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Femasys Inc. - Common Stock (NQ:FEMY)

1.090 -0.060 (-5.22%)
Streaming Delayed Price Updated: 12:04 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Femasys Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Analyst Expectations For Femasys's Future
Via Benzinga
Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update
From Femasys Inc.
Via GlobeNewswire
Femasys Reports Wider-Than-Expected Annual Loss, But Retail Continues To Be Optimistic
The company said that as of the end of 2024, it had an accumulated deficit of $127.2 million and cash and cash equivalents of only $3.5 million. 
Via Stocktwits
Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update
From Femasys Inc.
Via GlobeNewswire
The Latest Analyst Ratings For Femasys
Via Benzinga
Femasys Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Via Benzinga
Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations
Femasys continues to expand access and market share for its first-line infertility treatment option 
From Femasys Inc.
Via GlobeNewswire
Q1 Virtual Investor Summit: On-Demand Presentations Now Live
Via ACCESS Newswire
Assessing Femasys: Insights From 4 Financial Analysts
Via Benzinga
Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain
From Femasys Inc.
Via GlobeNewswire
Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach
First-in-world approval of FemBloc delivery system for women seeking permanent birth control 
From Femasys Inc.
Via GlobeNewswire
Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials
From Femasys Inc.
Via GlobeNewswire
Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices
UK regulatory approval follows FemaSeed, FemVue and FemCerv clearance/ approvals in the U.S., Europe, Canada and Israel 
From Femasys Inc.
Via GlobeNewswire
Femasys Announces Israeli Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices
Regulatory approval follows FemaSeed U.S. FDA-clearance announced September 2023 and EU CE mark approval announced June 2024 
From Femasys Inc.
Via GlobeNewswire
Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control
European patents expand coverage for both essential components of FemBloc for fallopian tube occlusion, resulting in non-surgical permanent contraception 
From Femasys Inc.
Via GlobeNewswire
Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment
From Femasys Inc.
Via GlobeNewswire
Femasys Announces Partnership with HRC Fertility, Esteemed Conglomerate Provider of Fertility Services in Western U.S., to Offer FemaSeed
HRC Fertility to begin providing FemaSeed infertility treatment to patients at centers across California 
From Femasys Inc.
Via GlobeNewswire
Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment
Trial results demonstrated safety and effectiveness of FemaSeed intratubal insemination with high satisfaction ratings from both practitioners and patients 
From Femasys Inc.
Via GlobeNewswire
Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update
Company accelerated commercialization with significant new partnerships both in the U.S. and Europe 
From Femasys Inc.
Via GlobeNewswire
Femasys to Exhibit at the Annual AAGL 2024 Global Conference
Premier conference focused on gynecological surgery 
From Femasys Inc.
Via GlobeNewswire
Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control
FemBloc issued patent provides additional coverage for Femasys’ therapeutic option for women seeking permanent birth control 
From Femasys Inc.
Via GlobeNewswire
Femasys Announces Partnership with Boston IVF, Prominent Network of Fertility Centers, to Offer FemaSeed
Boston IVF to begin providing FemaSeed as an infertility treatment option to expand access for patients across nearly 30 centers nationwide 
From Femasys Inc.
Via GlobeNewswire
Femasys to Exhibit at ASRM 2024 and Participate in the Congress’ KEEPR Education Program
Company’s VP of Education and Global Training Named Chairman of ASRM Corporate Member Council 
From Femasys Inc.
Via GlobeNewswire
Femasys to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
From Femasys Inc.
Via GlobeNewswire
Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments
From Femasys Inc.
Via GlobeNewswire
Femasys Announces Infertility Clinic Customers from Coast to Coast
Leading medical clinics become key regional resources to offer FemaSeed infertility treatment 
From Femasys Inc.
Via GlobeNewswire
Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market
Company taps Comercial Medico Quirurigca, SA and Durgalab as first EU distributors for its CE-marked women’s reproductive healthcare products 
From Femasys Inc.
Via GlobeNewswire
Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check
In addition to 510(k) clearance, FemChec, a contrast generating product, is an integral part of the confirmation test following administration of FemBloc non-surgical permanent birth control, currently... 
From Femasys Inc.
Via GlobeNewswire
Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Femasys to Exhibit at The Canadian Fertility and Andrology Society’s 70th Annual Meeting
From Femasys Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.